Wealth Enhancement Advisory Services
CPRX

Wealth Enhancement Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$992K Buy
31,530
+9,260
+42% +$273K ﹤0.01% 2075
2026
Q1 		$550K Sell
22,270
-7,234
-25% -$172K ﹤0.01% 2242
2025
Q4 		$666K Buy
29,504
+302
+1% +$6.73K ﹤0.01% 2258
2025
Q3 		$608K Sell
29,202
-2,553
-8% -$52.5K ﹤0.01% 2208
2025
Q2 		$681K Sell
31,755
-3,579
-10% -$84.5K ﹤0.01% 1985
2025
Q1 		$857K Buy
35,334
+13,915
+65% +$313K ﹤0.01% 1684
2024
Q4 		$447K Buy
21,419
+1,402
+7% +$30.1K ﹤0.01% 2072
2024
Q3 		$398K Buy
20,017
+1,989
+11% +$36.9K ﹤0.01% 1979
2024
Q2 		$279K Buy
18,028
+2,002
+12% +$31.2K ﹤0.01% 2032
2024
Q1 		$255K Buy
+16,026
New +$241K ﹤0.01% 2023
2023
Q4 		– Sell
-21,326
Closed -$249K – 2360
2023
Q3 		$249K Buy
+21,326
New +$285K ﹤0.01% 1855

Other funds holding CPRX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
OLA
Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Wealth Enhancement Advisory Services's CPRX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Catalyst Pharmaceutical (CPRX) stake by 42% in Q2 2026, buying an estimated $273K and bringing the position to 31,530 shares worth $992K. The position accounts for ﹤0.01% of the portfolio, ranked #2075.

Wealth Enhancement Advisory Services first reported a position in CPRX in Q3 2023 and has held it in 11 quarters since. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 31,530 shares of Catalyst Pharmaceutical worth $992K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 9,260 Catalyst Pharmaceutical shares in Q2 2026, an estimated $273K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2075 holding.
  • Wealth Enhancement Advisory Services first reported a position in Catalyst Pharmaceutical in Q3 2023 and has held it in 11 quarters since.
  • 36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.